COMMUNIQUÉS West-GlobeNewswire

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
03/06/2025
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1 -m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of [...]
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
03/06/2025
VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“ Eupraxia ” or the “ Company ”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Canadian Health Tech Cuts Hospital Emergency Department Triage Time by up to 60%
03/06/2025
Ontario-based digital health company EmergConnect reports up to 60% reductions in emergency room triage time at hospitals using its platform. Several major Ontario hospitals now use the system Photo Courtesy of [...]
Saus Trades’ Latest eBook Helps Traders Tackle the Psychological Barriers to Consistent Profitability
03/06/2025
The Trader’s Mind bridges the gap between strategy and success, offering tools like trading journals, breathing techniques, and mindset frameworks. Designed for daily use, it’s been embraced by over 20,000 traders, [...]
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
03/06/2025
Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase [...]
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
03/06/2025
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that [...]
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
03/06/2025
ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that [...]
Extendicare Acquires Nine Long-Term Care Homes from Revera
03/06/2025
MARKHAM, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“ Extendicare ”) (TSX: EXE.TO) announced today that, effective June 1, 2025, it has completed the previously announced transaction with Revera Inc. [...]
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
02/06/2025
Media Release COPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), [...]
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
02/06/2025
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025 BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP [...]
Cronos Group Inc. to Speak at the TD Cowen 9th Annual Future of the Consumer Conference
02/06/2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
LifeLabs partners with POGO to support their ongoing mission of helping Ontario children with cancer
02/06/2025
Toronto, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- LifeLabs, Canada’s leading medical laboratory, is proud to announce its continued partnership with the Pediatric Oncology Group of Ontario (POGO) to support Canadian [...]
Abivax Presents First Quarter 2025 Financial Results
02/06/2025
Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage [...]
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted 10 newly-hired [...]
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
02/06/2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the [...]
The Ensign Group Acquires Two Skilled Nursing Facilities in Idaho
02/06/2025
SAN JUAN CAPISTRANO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Adds Skilled Nursing Facility in California
02/06/2025
SAN JUAN CAPISTRANO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly [...]

Pages